First Trial Of Proton Pump Inhibitors To Begin In November

First Trial Of Proton Pump Inhibitors To Begin In November

Introduction

The federal court has scheduled to begin the first "bellwether" trial from the thousand lawsuits of Nexium and other proton pump inhibitors (PPI) on November 15, 2021.

The makers of Nexium, Prilosec, Prevacid, Protonix, and other PPI drugs currently have 13,000 claims pending against them with similar allegations that their products increase the risk of chronic kidney disease, acute kidney injury, kidney failure, and other side effects.

The U.S. District Judge Claire C. Cecchi issued a case management order on January 10, which states that the first 6 bellwether cases will have a generic discovery deadline of September 15, 2020, and the first trial will begin in November 2021.

According to an independent study published in the medical journal JAMA Internal Medicine, the risk of chronic kidney disease is more for the users of Nexium, Prilosec, and other PP1 as compared to non-users. Side effects of PPI include heart attacks, dementia, bone fractures, vitamin B deficiency, low magnesium levels, and gastric cancer.